Study of Serum Ferritin, Zinc, and Copper Levels in Children With Helicobacter pylori Gastritis and the Effect of the Treatment.
Eman Elsaadany, Saleh Amin, Maher Abdel-Hafez...
https://pubmed.ncbi.nlm.nih.gov/35929980/Actively Recruiting
Led by Tanta University · Updated on 2026-09-09
88
Participants Needed
1
Research Sites
8 weeks
Total Duration
Researchers are evaluating the safety and effectiveness of different triple therapy treatments to eradicate Helicobacter pylori infection, a bacterium that colonizes the stomach and can lead to serious gastrointestinal diseases including chronic gastritis, peptic ulcers, and gastric cancer. This phase 3 randomized controlled study compares proton pump inhibitor PPI based therapy and vonoprazan-based therapy, both with or without zinc supplementation, to determine their impact on H. pylori eradication and related biological markers. The study involves four treatment groups of 22 patients each. One group receives PPI-based triple therapy with omeprazole or pantoprazole, amoxicillin, and clarithromycin twice daily for 14 days, with another group receiving the same therapy plus zinc sulfate. The other two groups receive vonoprazan-based triple therapy with amoxicillin and clarithromycin, with one group also receiving zinc sulfate. Zinc is being studied for its potential to inhibit H. pylori growth and enhance treatment efficacy. Successful eradication will be confirmed at least 4 weeks after treatment. Participants will be monitored over 8 weeks, with assessments including stool antigen tests to confirm H. pylori eradication and blood tests measuring serum interleukin-6 and pepsinogen levels to evaluate inflammation and gastric health. The Gastrointestinal Symptom Rating Scale is also used to track symptom changes. The study will assess differences in eradication rates and changes in biomarkers and symptoms, providing important data on the comparative effectiveness of therapies with and without zinc supplementation.
CONDITIONS
Comparative Study Evaluating Safety and Effectiveness of ( Proton Pump Inhibitor Versus Vonoprazan ) Based Triple Therapy With or Without Zinc to Eradicate H. Pylori Infection
E
Eman A Mahmoud, Prof.
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Tanta University
Lead Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - 2 weeks
Participants receive one of four assigned triple therapy treatments with or without zinc, taken twice daily for 2 weeks.
Twice daily medication intake for 2 weeks
Duration - 8 weeks
Participants are monitored for 8 weeks after treatment to assess eradication of H. pylori and measure blood markers and symptoms.
Regular assessments including stool and blood tests
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
SUPPORTIVE_CARE
Number of Arms
4
Have more questions? Get in touch with our team for quick support
Eman Elsaadany, Saleh Amin, Maher Abdel-Hafez...
https://pubmed.ncbi.nlm.nih.gov/35929980/Károly R Kulich, Ahmed Madisch, Franco Pacini...
https://pubmed.ncbi.nlm.nih.gov/18237386/C S Goodwin, M M Mendall, T C Northfield
https://pubmed.ncbi.nlm.nih.gov/9014926/Norma Sánchez-Zauco, Javier Torres, Alejandro Gómez...
https://pubmed.ncbi.nlm.nih.gov/28558708/Faten A S Alsulaimany, Zuhier A Awan, Ahmad M Almohamady...
https://pubmed.ncbi.nlm.nih.gov/32283700/Zelai He, Hao Jiang, Xiangyu Zhang...
https://pubmed.ncbi.nlm.nih.gov/32946931/Min Nie, Dong Mei Deng, Yafei Wu...
https://pubmed.ncbi.nlm.nih.gov/32407890/Yucheng Wang, Ying Wang, Yuguang Wang...
https://pubmed.ncbi.nlm.nih.gov/29145971/Dongjie Fan, Yanan Gong, Lu Sun...
https://pubmed.ncbi.nlm.nih.gov/35660509/Andreea Ligia Dincă, Lorena Elena Meliț, Cristina Oana Mărginean
https://pubmed.ncbi.nlm.nih.gov/35884067/Tanta University
Lead Sponsor